Unpredicted adverse reaction to omalizumab

Despite promising reports of the use of omalizumab as add-on therapy in patients with systemic mastocytosis and recurrent anaphylaxis during specifi c venom immunotherapy (vit),unpredicted adverse effects may lead to therapy failure. we present the case of a patient with systemic mastocytosis and hymenoptera venom allergy who was dministered omalizumab as add-on therapy to improve vit tolerability after repeated severe adverse reactions despite h 1/h 2-antihistamine prophylaxis. we describe an nexpected discontinuation of omalizumab following successful initiation of vit in a patient with systemic mastocytosis,with subsequent lack of tolerability of vit. an nteresting aspect of this case is the correlation of basophil activation test results with both clinical tolerability and vit intolerance. © 2011 esmon publicidad.